Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
6 June 2022

ORYZON to give updates on corporate progress in June

29 June 2022

Annual General Shareholders’ Meeting 2022

5 May 2022

ORYZON reports results and corporate update for quarter ended March 31, 2022

3 May 2022

ORYZON starts preclinical collaboration on Kabuki syndrome with Kennedy Krieger Institute and Johns Hopkins University

24-26 May 2022

Foro MedCap BME

Madrid

Spain

24-25 May 2022

PrecisionMed Expo & Summit

Dubai

United Arab Emirates

23-26 May 2022

H.C. Wainwright Global Investment Conference

Miami

FL

United States

16-24 May 2022

BioEquity Europe

Milan

MI

Italy

10-11 May 2022

LSX World Congress

London

United Kingdom

2-3 May 2022

Swiss Biotech Day

Basel

Switzerland

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Current page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel